← Return to Aromatase Inhibitors: Did you decide to go on them or not?

Discussion
Comment receiving replies
@callalloo

Thank you for this and all you contribute here. I agreed with thr oncologist going forward. I'll stay current with self-exams and a schedule of doctors' exams and mammograms. And will do blood work every 3 months to keep an eye on tumor and other markers. And reserve the option to reconsider if variables change. So he and I are a team now and the patient portal is excellent for getting questions to the doctors and promised responses with 24 hours.

On a different note, your experience with a generic was interesting. Someone on another thread had a markedly better experience with the brand-name of an AI versus a generic of the same med. And someone elsewhere posted about very sudden side effects on a generic she'd been taking for a long time then discovered that her pharmacy had recently switched to a different manufacturer. Maybe people having side effects can benefit from just changing to the brand if possible or a different pharmacy to try it a different company's generic version. (We saved a pet's life once doing just that for what it's worth. )

Jump to this post


Replies to "Thank you for this and all you contribute here. I agreed with thr oncologist going forward...."

ps The Tailor X study was to help women with intermediate Oncotype DX scores decide on whether to have chemo or not. Low scores and high scores had a more clear path.

"Women in the trial who had a score in the intermediate range (11­–25) were randomly assigned to receive hormone therapy alone or hormone therapy with adjuvant chemotherapy. The goal was to assess whether women who received hormone therapy alone had outcomes that were as good as those among women who received chemotherapy in addition to hormone therapy." https://www.cancer.gov/news-events/press-releases/2018/tailorx-breast-cancer-chemotherapy

The study supported the use of hormonal meds only, without chemo, for these patients. "According to the authors, the new findings suggest that chemotherapy may be avoided in about 70 percent of women with HR-positive, HER2-negative, node-negative breast cancer." All participants were on hormonal meds.